The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics
Evolving Treatment Strategies in Transplant-Ineligible NDMM: Expert Insights From CEPHEUS, IMROZ and BENEFIT
Advancing Frontline Therapy in Transplant-Eligible Myeloma and Emerging Trends in Smoldering Myeloma Management
Managing Early Relapse in Transplant-Eligible MM and the Influence of Clonal Evolution
Why a Patient With Multiple Myeloma Might Decline Stem Cell Transplant: Mansi Shah, MD
How Transplant, CAR T, and Bispecifics Fit Into Myeloma Care: Mansi Shah, MD
Balancing Timing of ASCT: Insights on Delayed Transplantation and Long-Term Treatment Outcomes
Tailoring Maintenance Therapy by Patient Risk: Lenalidomide Alone vs Combination Approaches
Self-Administered Subcutaneous Isatuximab May Ease Multiple Myeloma Treatment Burden: Xavier Leleu, MD, PhD
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Closing Gaps in CLL Care: Managed Care Insights and Strategies
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens
Streamlining Transitions Between Academic and Community Centers